Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
Completed · Phase 3
Conditions studied: Breast Cancer, Osteoporosis
In brief
RATIONALE: It is not yet known whether zoledronate is effective in preventing bone loss in premenopausal women who are receiving adjuvant chemotherapy after undergoing surgery for early stage breast cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate in preventing bone loss in premenopausal women who are receiving chemotherapy after surgery for early stage breast cancer.
Key facts
- Study ID
- NCT00049452
- Run by
- Herbert Irving Comprehensive Cancer Center
- People needed
- 120
- Starts
- 2001-12-01
- Expected to finish
- 2008-08-01
- Last updated by the study team
- 2014-01-06
Who can join
Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Carl and Dorothy Bennett Cancer Center at Stamford Hospital — Stamford, Connecticut, United States
- Valley Hospital - Paramus — Paramus, New Jersey, United States
- Herbert Irving Comprehensive Cancer Center at Columbia University — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.